Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
China’s Food and Beverage Industry in Search of Methods to Shrink its Carbon Footprints
Exclusive Interview with Ray Hu, Founder and Managing Partner of Blue Lake Capital
Although the past two years have witnessed great changes in the world, the digitization trend remains unchanged. Of all the uncertainties facing us, digitization is still the surest opportunity nowadays.
Updated 10 hours ago
An Overview of China’s Robotaxi Industry in 2022 for Overseas Investors
This article discusses Robotaxi’s market size forecasting, commercialization barriers, relevant government policies and regulations, and the analysis of major players in China market. Also, the article includes some insights from Robotaxi executives and its supplier.
Updated 14 hours ago
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM